Department of Anesthesiology, Institute of Neurological Disease, West China Hospital, Sichuan University, No. 37 Guoxue lane, Chengdu, 610041, Sichuan, China.
Department of Neurosurgery, First Affiliated Hospital of Kunming Medical University, Kunming, 650000, Yunnan, China.
BMC Anesthesiol. 2022 Apr 29;22(1):130. doi: 10.1186/s12871-022-01670-0.
To investigated the effects of sufentanil in combination with flurbiprofen axetil and dexmedetomidine for patient-controlled intravenous analgesia (PCIA) on patients after open gastrointestinal tumor surgery, and compared this combination with traditional PCIA with pure opioids or epidural analgesia (PCEA).
Patients (n = 640) who underwent open gastrointestinal tumor surgery and received patient-controlled analgesia (PCA) were included. According to the type of PCA, patients were assigned to three groups: MPCIA (PCIA with sufentanil, flurbiprofen axetil, dexmedetomidine and metoclopramide), OPCIA (PCIA with sufentanil, tramadol and metoclopramide) and PCEA group (PCEA with sufentanil and ropivacaine). The characteristics of patients, intraoperative use of analgesics, postoperative visual analogue scale (VAS), postoperative adverse reactions and postoperative recovery were collected. The primary outcome was postoperative VAS score. One-way ANOVA, Kruskal-Wallis H test, Fisher exact probability method, and binary logistic regression analysis were used for analysis.
There were no significant differences in the characteristics of patients, operation time, tumor site and the use of postoperative rescue analgesics among the groups. In the first two days after open gastrointestinal tumor surgery, the VAS (expressed by median and interquartile range) of MPCIA (24 h, resting: 1,1; movement: 3,2. 48 h, resting: 0,1; movement: 2,1.) and PCEA (24 h, resting: 0,1; movement: 2,1. 48 h, resting: 0,1; movement: 2,2.) groups were significantly lower than those of OPCIA group (24 h, resting: 2.5,2; movement: 4,2. 48 h, resting: 1.5,1.75; movement: 3,1.) (all p < 0.01). The incidence of postoperative nausea and vomiting in MPCIA group was 13.6% on the first day after surgery, which was significantly higher than that in PCEA group. There was no significant difference in the incidence of other postoperative adverse events. Higher intraoperative sufentanil dosage (OR (95%CI) = 1.017 (1.002-1.031), p = 0.021), lower body mass index (OR (95%CI) = 2.081 (1.059-4.089), p = 0.033), and tumor location above duodenum (OR (95%CI) = 2.280 (1.445-3.596), p < 0.001) were associated with poor postoperative analgesia.
The analgesic effects of PCIA with sufentanil in combination with flurbiprofen axetil and dexmedetomidine on postoperative analgesia was better than that of traditional pure opioids PCIA, and similar with that of PCEA.
研究舒芬太尼联合氟比洛芬酯和右美托咪定用于胃肠肿瘤手术开放患者的患者自控静脉镇痛(PCIA)的效果,并将其与传统的单纯阿片类药物 PCIA 或硬膜外镇痛(PCEA)进行比较。
纳入接受胃肠肿瘤开放手术和接受患者自控镇痛(PCA)的患者(n=640)。根据 PCA 的类型,患者被分为三组:MPCIA(PCIA 用舒芬太尼、氟比洛芬酯、右美托咪定和甲氧氯普胺)、OPCIA(PCIA 用舒芬太尼、曲马多和甲氧氯普胺)和 PCEA 组(PCIA 用舒芬太尼和罗哌卡因)。收集患者特征、术中镇痛药使用、术后视觉模拟评分(VAS)、术后不良反应和术后恢复情况。主要结局指标为术后 VAS 评分。采用单因素方差分析、Kruskal-Wallis H 检验、Fisher 确切概率法和二项逻辑回归分析进行分析。
三组患者的一般情况、手术时间、肿瘤部位和术后解救性镇痛药使用无统计学差异。在胃肠肿瘤开放手术后的前两天,MPCIA(24 h,静息:1,1;运动:3,2。48 h,静息:0,1;运动:2,1.)和 PCEA(24 h,静息:0,1;运动:2,1. 48 h,静息:0,1;运动:2,2.)组的 VAS(中位数和四分位距表示)明显低于 OPCIA 组(24 h,静息:2.5,2;运动:4,2. 48 h,静息:1.5,1.75;运动:3,1.)(均 p<0.01)。MPCIA 组术后第一天恶心呕吐发生率为 13.6%,明显高于 PCEA 组。其他术后不良反应发生率无统计学差异。术中舒芬太尼用量较高(OR(95%CI)=1.017(1.002-1.031),p=0.021)、体重指数较低(OR(95%CI)=2.081(1.059-4.089),p=0.033)、肿瘤位于十二指肠以上(OR(95%CI)=2.280(1.445-3.596),p<0.001)与术后镇痛效果差相关。
舒芬太尼联合氟比洛芬酯和右美托咪定用于胃肠肿瘤手术开放患者的 PCIA 的镇痛效果优于传统单纯阿片类药物 PCIA,与 PCEA 相似。